The company has achieved a notable improvement in financial stability, successfully reducing its debt-to-equity ratio from 3.80 in 2024Q3 to 0.60 by 2026Q1.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'11 | Dec'10 |
|---|
| Total Current Assets | 579.65M | 538.81M | 292.48M | 90.85M | 97.97M | 154.02M | 135.51M | 45.74M | 305.42K | 55.08K | 507.93K | 7.63M | 1.76M | 2.22M |
| Cash & Short-Term Investments | 207.35M | 185.57M | 43.58M | 22M | 34.26M | 36.12M | 25.51M | 8M | 119.27K | 9.45K | 10.52K | 122.29K | 224.8K | 465.55K |
| Cash Only | 207.35M | 185.57M | 43.58M | 22M | 34.26M | 36.12M | 25.51M | 8M | 119.27K | 9.45K | 10.52K | 122.29K | 224.8K | 465.55K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 339.56M | 325.42M | 236.05M | 62.78M | 58.32M | 114.76M | 108.14M | 36.14M | 186.15K | 6.25K | 15K | 0 | 720.87K | 613.65K |
| Days Sales Outstanding | 145.94 | 135.71 | 179.52 | 92.52 | 97.06 | 126.34 | 144.04 | 135.91 | 743.6 | 42.55 | - | - | 103.24 | 176.87 |
| Inventory | 4.68M | 2.87M | 2.85M | 3.39M | 3.53M | 2.81M | 1.73M | 899.91K | 27.07K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 2.56 | 2.43 | 3.67 | 5.81 | 6.33 | 6.75 | 5.41 | - | 158.62 | - | - | - | - | - |
| Other Current Assets | 28.06M | 24.95M | 10M | 0 | 1.87M | 323.28K | 0 | 0 | -27.07K | 39.38K | 482.41K | 7.27M | 754.77K | 812.73K |
| Total Non-Current Assets | 377.67M | 379.71M | 362.84M | 307.4M | 333.78M | 240.63M | 173.05M | 133.48M | 144.01K | 3.27M | 2.9K | 3.38K | 313.77K | 116.11K |
| Property, Plant & Equipment | 342.18M | 343.9M | 324.69M | 269.39M | 295.15M | 238.36M | 170.81M | 131.28M | 7.61K | 3.85K | 1.18K | 1.66K | 18.56K | 5.09K |
| Fixed Asset Turnover | 2.61x | 2.55x | 1.48x | 0.92x | 0.74x | 1.39x | 1.60x | 0.74x | 12.00x | 13.95x | - | - | 137.30x | 248.94x |
| Goodwill | 13.92M | 13.92M | 13.92M | 17.07M | 17.01M | 1.14M | 1.14M | 3.47M | 0 | 0 | 0 | 0 | 111.03K | 111.03K |
| Intangible Assets | 20.91M | 21.23M | 15.53M | 20.51M | 21.19M | 682.65K | 0 | 1.54M | 2.57M | 3.27M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100K | 116.96K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 668K | 662K | 711.35K | 431.13K | 423.43K | 456.08K | 1.1M | -2.81M | 19.43K | 1.95K | 1.72K | 1.72K | 0 | 0 |
| Total Assets | 957.32M | 918.52M | 655.32M | 398.25M | 431.75M | 394.65M | 308.55M | 179.22M | 449.43K | 3.33M | 510.83K | 7.64M | 2.07M | 2.33M |
| Asset Turnover | 0.96x | 0.95x | 0.73x | 0.62x | 0.51x | 0.84x | 0.89x | 0.54x | 0.20x | 0.02x | - | - | 1.23x | 0.54x |
| Asset Growth % | 284.88% | 40.16% | 64.55% | -7.76% | 9.4% | 27.9% | 72.16% | 39778.36% | -86.5% | 551.63% | -93.31% | 268.48% | -11.2% | - |
| Total Current Liabilities | 184.44M | 157.91M | 140.87M | 58.31M | 54.86M | 37.69M | 31.45M | 72.13M | 1.04M | 959.78K | 6.38M | 6.08M | 288.58K | 351.62K |
| Accounts Payable | 46.45M | 48.97M | 13.96M | 25.28M | 23.93M | 17.65M | 8.63M | 1.75M | 567.01K | 348.35K | 356K | 168.97K | 263.19K | 326.23K |
| Days Payables Outstanding | 34.55 | 41.47 | 17.96 | 43.35 | 42.84 | 42.32 | 27.06 | - | 3.32K | 225.3 | 274.72K | 93.16K | 62.81 | 152.04 |
| Short-Term Debt | 26.27M | 14.08M | 17.95M | 14.18M | 15.17M | 10.23M | 18.65M | 13.35M | 477.06K | 386.19K | 50K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 173.92K | 38.65K | 165.56K | 9.19K | 9.1K | 0 | 811.23K | 0 | 0 |
| Other Current Liabilities | 111.72M | 8.26M | 0 | 0 | 5.61M | 3.6M | -38.65K | 3.37M | 332.19K | 216.14K | 5.97M | 5.1M | 25.39K | 25.39K |
| Current Ratio | 3.14x | 3.41x | 2.08x | 1.56x | 1.79x | 4.09x | 4.31x | 0.63x | 0.29x | 0.06x | 0.08x | 1.26x | 6.10x | 6.31x |
| Quick Ratio | 3.12x | 3.39x | 2.06x | 1.50x | 1.72x | 4.01x | 4.25x | 0.62x | 0.27x | 0.06x | 0.08x | 1.26x | 6.10x | 6.31x |
| Cash Conversion Cycle | 113.95 | 96.66 | 165.22 | 54.99 | 60.55 | 90.77 | 122.39 | - | -2.42K | - | - | - | - | - |
| Total Non-Current Liabilities | 330.83M | 337.18M | 312.56M | 260.83M | 256.56M | 165.38M | 129.73M | 56.26M | 902.72K | 0 | 0 | 0 | 181.69K | 0 |
| Long-Term Debt | 298.41M | 29.17M | 22.47M | 26.31M | 23.05M | 78.82M | 81.9M | 40.88M | 902.72K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 888.23M | 298.91M | 290.1M | 229.37M | 223.06M | 86.56M | 47.83M | 15.38M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 32.2M | 9.09M | 0 | 5.15M | 10.45M | 1.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 24.26M | 0 | 0 | 0 | 0 | -1.75M | 0 | 0 | 0 | 0 | 0 | 0 | 181.69K | 0 |
| Total Liabilities | 515.26M | 495.09M | 453.43M | 319.14M | 311.42M | 203.07M | 161.19M | 128.39M | 1.95M | 959.78K | 6.38M | 6.08M | 470.27K | 351.62K |
| Total Debt | 324.68M | 351.39M | 340.3M | 275.76M | 267.2M | 178.55M | 150.12M | 119.94M | 1.38M | 386.19K | 50K | 0 | 0 | 0 |
| Net Debt | 117.33M | 165.82M | 296.72M | 253.75M | 232.95M | 142.43M | 124.61M | 111.94M | 1.26M | 376.74K | 39.48K | -122.29K | -224.8K | -465.55K |
| Debt / Equity | 0.60x | 0.83x | 1.69x | 3.49x | 2.22x | 0.93x | 1.02x | 2.36x | - | 0.16x | - | - | - | - |
| Debt / EBITDA | 1.09x | 1.19x | 2.27x | - | - | 1.00x | 0.94x | 3.23x | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.39x | 0.56x | 1.98x | - | - | 0.80x | 0.78x | 3.01x | - | - | - | - | - | - |
| Interest Coverage | 9.13x | 12.01x | 6.51x | -1.97x | -32.60x | 28.35x | 23.66x | 10.09x | -1.31x | -15.35x | -173.90x | -169.42x | - | - |
| Total Equity | 537.81M | 423.44M | 201.89M | 79.11M | 120.33M | 191.58M | 147.37M | 50.84M | -1.5M | 2.37M | -5.87M | 1.56M | 1.6M | 1.99M |
| Equity Growth % | 965.17% | 109.73% | 155.22% | -34.26% | -37.19% | 30% | 189.89% | 3495.03% | -163.21% | 140.36% | -475.93% | -2.58% | -19.27% | - |
| Book Value per Share | 74.93 | 62.67 | 39.59 | 17.94 | 28.43 | 48.48 | 34.34 | 12.28 | -0.21 | 0.57 | -2.84 | 0.76 | 1.34 | 1.66 |
| Total Shareholders' Equity | 442.05M | 329.45M | 146.34M | 61.45M | 95.86M | 114.65M | 85.81M | 28.31M | -1.5M | 2.37M | -5.87M | 1.56M | 1.6M | 1.99M |
| Common Stock | 7K | 7K | 5.51K | 676.68K | 650.22K | 592.79K | 5.28K | 4.65K | 1.77K | 126.2K | 39.71K | 39.68K | 0 | 0 |
| Retained Earnings | -239.38M | -286.19M | -356.89M | -409.07M | -363.29M | 102.32M | -18.22M | -12.57M | -5.45M | -9.65M | -10.23M | -2.8M | -824.45K | -441.06K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1M | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 95.76M | 93.99M | 55.55M | 17.65M | 24.46M | 76.93M | 61.56M | 22.53M | 0 | 0 | 0 | 0 | 0 | 0 |
Regulatory reimbursement volatility
As reported in financial statements, Nutex Health has successfully reduced its debt-to-equity ratio from 3.80 in 2024Q3 to 0.60 by 2026Q1, signaling a significant shift toward a more conservative capital structure that may provide a buffer against the inherent volatility of its micro-hospital business model.
The dramatic improvement in the debt-to-equity ratio appears driven by both a reduction in total debt and a substantial expansion of the equity base. This trajectory suggests management is prioritizing balance sheet stability, which may be a strategic necessity given the regulatory and reimbursement risks inherent in the emergency care sector.
Based on the company's reported figures, the current ratio has improved from 1.56 in 2023Q4 to 3.14 in 2026Q1, reflecting a robust accumulation of cash reserves that now stand at $207.3 million, providing the firm with significant dry powder for potential future facility expansions or operational contingencies.
The expansion of the current ratio suggests that the company is effectively managing its short-term obligations relative to its liquid assets. Investors should monitor whether this liquidity is being held to offset potential future cash flow volatility or if it represents capital awaiting deployment into new high-acuity nodes.
According to recent SEC filings, the company's equity base has grown from $61.5 million in 2023Q4 to $442.1 million in 2026Q1, despite the persistence of significant negative retained earnings, which suggests that capital infusions or equity-based financing have been the primary drivers of balance sheet growth.
The disconnect between the rising equity position and the ongoing accumulation of negative retained earnings warrants further investigation into the quality of the capital structure. It appears that the firm is relying on external equity support to sustain its growth, which may dilute long-term shareholder value if operational profitability does not materialize.
As indicated by the balance sheet data, net property, plant, and equipment (PPE) has increased to $342.2 million as of 2026Q1, confirming that the company's business model remains inherently asset-heavy due to the physical requirements of maintaining a decentralized network of 21 emergency-grade micro-hospital facilities.
The concentration of assets in PPE highlights the high fixed-cost nature of the hospital division, which requires consistent patient volume to achieve operating leverage. The relatively low level of goodwill suggests that the asset base is primarily composed of tangible infrastructure, which may offer more tangible value than intangible-heavy peers.
Quick answers to the most common questions about buying NUTX stock.
As of 2025, Nutex Health, Inc. (NUTX) had total assets of $918.5M including $538.8M in current assets.
Nutex Health, Inc. (NUTX) carries total debt of $351.4M, offset by $185.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Nutex Health, Inc. (NUTX) has total shareholders' equity (book value) of $329.4M ($62.67 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Nutex Health, Inc. (NUTX) reported a current ratio of 3.41x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.